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ABSTRACT
Plasmodium vivax is traditionally known to cause benign tertian malaria, although recent reports suggest 
that P. vivax can also cause severe life-threatening disease analogous to severe infection due to P. falciparum. 
There are limited published data on the clinical and epidemiological profiles of children suffering from 
‘severe malaria’ in an urban setting of India. To assess the clinical and epidemiological profiles of children 
with severe malaria, a prospective study was carried out during June 2008–December 2008 in the Depart-
ment of Pediatrics, Guru Teg Bahadur Hospital, a tertiary hospital located in East Delhi, India. Data on 
children aged ≤12 years, diagnosed with severe malaria, were analyzed for their demographic, clinical and 
laboratory parameters. All patients were categorized and treated as per the guidelines of the World Health 
Organization. In total, 1,680 children were screened for malaria at the paediatric outpatient and casualty 
facilities of the hospital. Thirty-eight children tested positive for malaria on peripheral smear examination 
(2.26% slide positivity rate). Of these, 27 (71%) were admitted and categorized as severe malaria as per 
the definition of the WHO while another 11 (29%) received treatment on outpatient basis. Most (24/27; 
88.8%) cases of severe malaria (n=27) were infected with P. vivax. Among the cases of severe malaria caused 
by Plasmodium vivax (n=24), 12 (50%) presented with altered sensorium (cerebral malaria), seven (29.1%) 
had severe anaemia (haemoglobin <5 g/dL), and 17 (70.8%) had thrombocytopaenia, of which two had 
spontaneous bleeding (epistaxis). Cases of severe vivax malaria are clinically indistinguishable from severe 
falciparum malaria. Our study demonstrated that majority (88.8%) of severe malaria cases in children from 
Delhi and adjoining districts of Uttar Pradesh were due to P. vivax-associated infection. P. vivax should, thus, 
be regarded as an important causative agent for severe malaria in children.
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INTRODUCTION
Malaria continues to be a major public-health prob-
lem in most tropical countries. As per the World 
Malaria Report 2009, there were 1.53 million con-
firmed cases of malaria from India, of which 0.77 
million were due to Plasmodium falciparum (1). 
Jharkhand, Orrisa, Chhattisgarh, Madhya Pradesh, 
and West Bengal contributed to half of the total 
malaria cases in India (2). Urban malaria consti-
tutes 15% of the burden of the disease in India (2). 
Mortality is very high in untreated severe forms of 
malaria. Cerebral malaria and anaemia are the two 
most important manifestations of severe malaria in 
children. 
Traditionally, severe malaria has been associated 
with infection due to P. falciparum. Recent studies 
from South-East Asia have highlighted P. vivax as a 
major cause of morbidity and mortality in infants 
and children (3,4). Data on the clinical and epide-
miological profiles of children with severe malaria 
from urban centres are limited. Hence, we analyzed 
the profile of severe malaria in children who were 
admitted to a tertiary centre located in East Delhi, 
catering to population from Delhi and adjoining 
districts of Uttar Pradesh, India.  
MATERIALS AND METHODS
Study design and setting
A prospective study was conducted during June 
–December 2008 in a tertiary-care hospital located 
in East Delhi, which caters to population from Del-Kaushik JS et al.
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hi and nearby districts (Ghaziabad, Meerut, Bagh-
pat, Kannoj, and Bulandshahr of Uttar Pradesh).
Enrollment
The study was conducted among children aged less 
than or equal to 12 years. Children with a short du-
ration (<3 days) of fever (temperature >38 °C) with-
out any localized symptoms were screened from 
the paediatric outpatient and casualty. 
Procedure
The diagnosis of malaria, including identification 
of species, was established by examination of thick 
and thin smears of peripheral blood. Slides were 
prepared, stained with Giemsa, and examined un-
der an oil immersion microscope. At least 100 
high-power fields (40X) of the thick smears were 
examined to rule out malaria. Malarial antigen test 
(optiMAL) and real-time polymerase chain reaction 
(PCR) could not be done due to their non-availa-
bility at our centre, although these are considered 
better sensitive methods for the detection of Plas-
modium species. 
The demographic profile, clinical features, and 
clinical course of illness were recorded. A baseline 
haemogram with platelet count, blood sugar, se-
rum creatinine, prothrombin time, partial throm-
boplastin time, blood lactate, pH estimation, urine 
examination, and chest skiagram were performed 
in all the cases. Investigations, such as cerebrospi-
nal fluid examination, urine culture, blood culture, 
neuroimaging, ultrasonography of abdomen, and 
liver function tests (serum bilirubin and serum 
aminotransferases), were conducted where deemed 
essential. 
Diagnosis and treatment protocol
Based on the clinical and laboratory parameters, 
children who were categorized as severe malaria as 
per the guidelines of the World Health Organiza-
tion (WHO) were included in the study (5). Chil-
dren diagnosed with severe malaria were treated 
with either intravenous quinine (20 mg/kg, fol-
lowed by 10 mg/kg tid for 7 days) or intravenous 
artesunate (2.4 mg/kg stat, followed by 2.4 mg/kg 
after 12 hours, then once a day for 7 days). When 
the patient was able to accept orally, s/he was shift-
ed to either oral quinine or oral artesunate accom-
panied with clindamycin, 15 mg/kg/day, orally, 
for seven days (5). Children with uncomplicated 
malaria were treated with artemisinin combination 
therapy (ACT) or with oral chloroquine (10 mg/kg 
stat, followed by 5 mg/kg after six hours, 24 hours, 
and 48 hours) in the case of P. vivax. Primaquine 
was given in the dose of 0.25 mg/kg/day for 14 days 
in the case of P. vivax and a single dose of 0.75 mg/
kg for P. falciparum.
Ethical aspects
The study protocol was fully explained to the par-
ents/guardians, and informed written consent was 
obtained before recruitment.
RESULTS
In total,1,680 children were screened for malarial 
infection in our centre during the study period. 
Of these, 38 children tested positive for malaria 
on peripheral smear examination, yielding a slide 
positivity rate of 2.26%. Of these, 35 (92.1%) were 
caused by P. vivax, and the remaining three cases 
were caused by P. falciparum (7.9%). Twenty-sev-
en cases were categorized as severe malaria as per 
the guidelines of the WHO and were admitted for 
treatment. The remaining 11 children (all having 
P. vivax-associated malaria) received treatment as 
outpatients.
Among the children with severe malaria, P. vivax 
was documented in 24 (88.8%) and P. falciparum 
in three cases (11.1%). The clinical and labora-
tory profiles of children with severe vivax malaria 
are presented in the table. The age of the patients 
with severe vivax malaria (n=24) ranged from eight 
months to 12 years; 18 (75%) of them were male. 
Fever was the chief presenting complaint in all the 
patients (100%), with a median duration of six 
(range 2-9) days. Other presenting complaints of 
children with severe vivax malaria were: repeated 
vomiting (n=18; 75%), altered sensorium/encepha-
lopathy (n=12; 50%), seizures (n=8; 33.3%), and 
epistaxis (n=2; 8.3%). The clinical signs among 
these patients included hepatomegaly (24; 100%), 
splenomegaly (n=22; 91.6%), pallor (n=20; 83.3%), 
icterus (n=2; 8.3%), and respiratory distress (n=2; 
8.3%). Thirteen (54%) children had more than one 
manifestation of severe malaria. Of the 12 children 
with encephalopathy, eight had multiple convul-
sions, two had severe anaemia requiring blood 
transfusion, and one had spontaneous bleeding. 
Lumbar puncture was done in 10 of the 12 children 
presenting with altered sensorium, which were all 
acellular with normal cerebrospinal fluid biochem-
ical parameters.
Seven (29.1%) patients with severe anaemia (hae-
moglobin <5 g/dL) required blood transfusion. 
Thrombocytopenia (platelet <1.5 lakh/dL) was ob-
served in 17 (70.8%) children while acute renal fail-
ure (serum creatinine >1.5 mg/dL) was seen in two 
(8.3%) cases. Of the 24 children with severe vivax 
malaria, two also had lobar pneumonia requiring 
intravenous antibiotics (ceftriaxone and cloxacil-Kaushik JS et al. Severe malaria among children in Delhi
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Table. Clinical and laboratory features of se- 
vere vivax malaria
Severe vivax 
malaria
No. of patients 
(n=24)
%
Clinical features
  Impaired     
  consciousness 12 50
  Multiple   
  convulsions 8 33.3
  Respiratory  
  distress 2 8.3
  Circulatory  
  collapse or shock 2 8.3
  Abnormal  
  spontaneous    
  bleeding 2 8.3
Laboratory features
  Severe anaemia   
  (Hb <5 g/dL) 7 29.1
Thrombocytopaenia 17 70.8
  Renal impairment 2 8.3
lin). Blood and urine cultures were sterile in all the 
children. 
All the patients with severe vivax malaria responded 
to intravenous quinine. Two patients with acute re-
nal failure were started on intravenous artesunate, 
followed by oral therapy once the patient started 
accepting orally, for seven days. All the cases of un-
complicated malaria were treated with oral chloro-
quine as none of the patients could afford ACT. The 
outcome of the patients was favourable in all the 
cases with severe vivax malaria. However, one child 
diagnosed as cerebral malaria due to P. falciparum-
associated infection died within a few hours of hos-
pitalization.
DISCUSSION
The present study showed a surge of cases of severe 
malaria caused by P. vivax among children residing 
in East Delhi and neighbouring districts of Uttar 
Pradesh during the study period. Clinical features 
of severe malaria caused by P. vivax were similar to 
those caused by P. falciparum, which included al-
tered sensorium, severe anaemia, and thrombocy-
topaenia. These data on severe vivax malaria are in 
line with those reported from Papau New Guinea 
and Indonesia (3,4).  
Manifestations of severe vivax malaria include se-
vere anaemia, respiratory distress, coma, malnutri-
tion, splenic rupture, thrombocytopaenia, and acute 
renal failure and shock. Features of severe vivax 
malaria in our study were cerebral malaria, severe 
anaemia, and thrombocytopaenia. There has been a 
recent surge of cases of cerebral malaria caused by P. 
vivax (6,7). Sequestration of infected red blood cells 
in cerebral vessels is a feature of cerebral malaria. 
Results of a study by Kochar et al. showed that vivax 
malaria can have both sequestration-related and 
non-sequestration-related complications of severe 
malaria, including cerebral malaria (8). Profound 
thrombocytopaenia is uncommon in malaria due 
to P. vivax, although it is well-documented in P. fal-
ciparum-associated malaria (9). It could be a result 
of direct lysis of platelets by P. vivax or by immu-
nological destruction by platelet-associated IgG an-
tibody. We observed thrombocytopaenia in 74.1% 
of the malarial children, a significantly high pro-
portion, although similar paediatric cases have 
been reported earlier (10). 
Co-morbidities are common in endemic areas of 
malaria and could contribute significantly to mor-
tality among cases of severe vivax malaria (11). Our 
patients of severe vivax malaria had co-morbidity 
of severe anaemia (29.1%), pneumonia (8.3%), 
acute renal failure (8.3%), and respiratory distress 
(8.3%). Despite the high rates of co-morbidities and 
severe manifestation of vivax malaria, the mortali-
ty rate in our study was nil. The mortality rate 
in severe vivax malaria ranged from 0.8% to 1.6% 
(12). This implies that timely initiation of treat-
ment with recommended antimalarial therapy, 
along with other supportive management, could 
lead to the low-mortality outcome. 
There has been an epidemiological change in the 
pattern of severe malaria in our region where P. fal-
ciparum was mostly considered the causative agent 
(13). A possible explanation for this emerging trend 
may be due to increase in migrant population in 
Delhi owing to more job opportunities and devel-
opment of resettlement colonies bringing in a fresh 
cohort of children with different immune status 
and, hence, susceptibility to Plasmodium infection. 
Also, the increase in construction activities in and 
around Delhi has led to an increased breeding of 
mosquitoes and, hence, a rise in mosquito-borne 
diseases, including malaria and dengue. Since P. 
vivax was considered less virulent, surveillance re-
ports in the past had primarily focused on P. fal-
ciparum. This could also explain the limited data 
available on the clinical features of severe malaria 
due to P. vivax. The emergence of severe malaria 
due to P. vivax as observed in our study might have 
important implications for the community with re-
spect to treatment and prevention strategies. 
The emergence of severe malaria caused by P. vivax 
could have significant implications in planning 
the malaria-control programmes for the commu-Kaushik JS et al.
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nity. The widespread use of ACT for severe malaria 
as per the guidelines of the WHO could result in 
the emergence of resistant parasite strains. It may 
be rational to continue the use of chloroquine for 
malaria due to P. vivax in chloroquine-sensitive ar-
eas. In places where both P. vivax and P. falciparum 
co-exist, measures need to be equally targeted to P. 
vivax to decrease morbidity and mortality due to 
severe malaria.   
The present study highlighted the change in the 
epidemiology of childhood severe malaria in the 
urban setting of North India. However, annual 
reporting with multicentric design of prospective 
studies is required to establish and confirm this 
trend. 
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